Skip to content
Home » Biotechnology

Biotechnology

Biotechnology Industry Key Financial Data 2023

The following analysis considers the 165 major publicly listed biotechnology companies with a market capitalisation above $1 billion. The numbers in the tables are expressed in millions of dollars except for percentages and ratios.

Number 165
Expected Growth Rate 11,95%
Financials 2023
Total Revenues  $ 250.528,00
Operating Income   $   36.137,00
Free Cash Flows Firm  $     4.114,09
Effective Tax Rate  2,44%
10Y Median Operating Ratios
 Revenues Growth  7,9%
 Gross Margin  68,9%
Operating Margin 30,9%
Reinvestment Margin 19,3%
ROIC 24,5%
Sales to IC 0,66
Solvency Ratios
Debt to EV 2,3%
Debt to Equity 8,5%
Interest Coverage  0,00
Rating  D2/D
Spread 20,00%
Beta
Unlevered Beta 2 y 0,86
Unlevered Beta 5 y 0,70

In 2023 the biotechnology industry generated $250.5 billion in revenues, a decrease of -6.9% from the $269 billion of 2022.

Over the past 10 years, the median growth rate in revenues has been 7.9%.

Year Total Revenues
2023 250.528
2022 269.098
2021 263.716
2020 190.820
2019 154.324
2018 141.080
2017 132.541
2016 124.553
2015 117.287
2014 99.357
2013 76.953
2012 70.150

Overall, the biotechnology industry registered an operating income of $36.1 billion in 2023. Regarding profitability, the 10-year median gross margin is 68.9%, while the 10-year median operating margin is equal to 30.9%.

Year Operating Income 
2023 36.137
2022 71.485
2021 85.964
2020 46.684
2019 42.907
2018 41.318
2017 45.382
2016 46.703
2015 47.896
2014 34.549
2013 22.173
2012 21.662

The total free cash flows to the firm for the biotechnology industry instead, were equal to $4.1 billion in 2023.

Moving on to efficiency ratios, the biotechnology industry’s 10-year median return on invested capital (ROIC) is 24.5%, while the 10-year median sales to invested capital is equal to 0.66.

The 10-year median reinvestment margin for the biotechnology industry – expressed as total reinvestments in net capital expenditures, acquisitions, and R&D divided by total revenues – is 19.3%.

Multiplying the reinvestment margin, which shows how much biotechnology companies have invested over the past years, by the sales to invested capital ratio, showing how efficiently biotechnology companies have invested, is it possible to calculate the expected growth rate in revenues for the biotechnology industry, equal to 11.95%.

Check out this post for a detailed explanation of how to calculate future revenue growth rates.

Median Expected Growth Rate
11,95%
Year Reinvestment Margin Sales To IC
2023 19,32% 0,51
2022 7,73% 0,57
2021 7,50% 0,66
2020 41,32% 0,04
2019 24,85% 0,67
2018 11,71% 0,59
2017 20,61% 0,61
2016 15,30% 0,70
2015 24,39% 0,90
2014 15,13% 0,87
2013 32,27% 0,75

As regards solvency ratios, the debt-to-enterprise value ratio for the biotechnology industry is 2.3%, while the debt-to-equity ratio is 8.5%.

Finally, the unlevered beta of the biotechnology industry – which is the beta depurated by the debt leverage – has been 0.86, for the past 2 years, and 0.7, for the past 5 years.

However, the beta is only one of the required inputs to calculate the appropriate discount rate for company valuation, check out this page where you can find the equity risk premium for different markets needed to calculate the required cost of equity.